Amyotrophic Lateral Sclerosis (ALS) Market

SKU: DMPH2089 | Last Updated On: Sep 28 2022 | Available Formats

>Amyotrophic Lateral Sclerosis (ALS) Market Expected to reach at a high CAGR of 5.6% by 2029:

Amyotrophic Lateral Sclerosis (ALS) Market is segmented By Drug (Rilutek (Riluzole), Edaravone (Radicava), Others), By Treatment Type (Physical therapy, Speech Therapy, Medication, Respiratory Therapy, Others), By End-User (Diagnostic centers, Hospitals, Clinics, Research & Academic Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.

 

Amyotrophic Lateral Sclerosis (ALS) Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.6% during the forecast period (2022-2029).

Amyotrophic Lateral Sclerosis (ALS) Market

Metrics

Details

Market CAGR

5.6%

Segments Covered

By Drug, By Treatment Type, By End-User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a neurological disease that affects the nerve cells (neurons) responsible for controlling voluntary muscle movement that affects nerve cells in the brain and spinal cords, which controls the activity of voluntary muscles.

Market Dynamics

The amyotrophic lateral sclerosis (ALS) market is growing due to several factors, such as rising ALS incidence, treatment awareness, increasing pipeline products, and favorable reimbursement policies.

The rising focus on research and development is expected to drive market growth.

Due to the high number of unmet needs, manufacturers focus on research and developments in treatment options, which would further drive the ALS treatment market's growth globally. The ALS clinical pipeline is strong and diverse, including late-stage programs that aim at enhancing muscle function, immune modulation, and neuroprotection, as well as mid or early-stage gene therapy or gene silencing approaches, stem-cell therapies, and immune-targeting agents and experts contend that regimens combining multiple mechanisms of action could hold significant clinical promise in the management of ALS. Thus, developers' considerable commercial opportunity to overcome the scientific and clinical hurdles blocking the path to regulatory approval to treat this devastating disease.

The rareness of diseases and high development cost hinders global amyotrophic lateral sclerosis (ALS) market growth.

However, the disease's rarity, high developmental cost and stringent regulations will hamper the growth of the global Amyotrophic Lateral Sclerosis (ALS) Market.

Industry analysis.

The global amyotrophic lateral sclerosis (ALS) market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing, and pipeline analysis.

Segment Analysis

Edaravone (Radicava) is expected to dominate the amyotrophic lateral sclerosis (ALS) market throughout the forecast period (2022-2029).

Radicava remains patent-protected, but Rilutek, launched in 1995, and its patent expired in 2013, followed by cheap generic versions of the drug on the market. In 2021, Rilutek (Riluzole) accounted for the largest revenue-generating segment because riluzole was the only approved drug for ALS treatment. However, the patent expiry of Rilutek in 2013 has negatively impacted the ALS treatment market growth. On the other hand, Edaravone (Radicava) is expected to show the highest growth rate during the forecast period (2022-2029), owing to its applicability and higher cost. Edaravone (Radicava) is another treatment in infusion therapy approved by the FDA to treat ALS. It guards nerve cells and slows disease progression by removing the reactive oxygen species. The treatment has been shown to decelerate the reduction in physical functioning in some ALS patients.

Geographical Analysis

The North American region holds the largest market share of the global Amyotrophic Lateral Sclerosis (ALS) market.

North America held the dominant market share for amyotrophic lateral sclerosis (ALS) in 2021. It is expected to maintain the growth over the forecast period (2022-2029) owing to the factors such as the increasing geriatric population and since a majority of people who develops ALS are of age forty to seventy, thereby rising prevalence of neurological diseases, higher treatment awareness, rising funding by the government agencies and private organizations in the healthcare system. According to the ALS Association, approximately 5,000 people in the U.S. are diagnosed with ALS yearly, which averages 15 new cases daily. Furthermore, the growing geriatric population in North America is fueling its dominance over the global market; for instance, according to the Census Bureau's 2020 population estimates, more than 55 million Americans are age 65 or older.

Competitive Landscape

The amyotrophic lateral sclerosis (ALS) market is highly competitive with many players. Some of the major players in the global amyotrophic lateral sclerosis (ALS) market are Brainstorm Cell Therapeutics, Sanofi, Biogen, Bausch Health, Roche, Ionis Pharmaceuticals, Apotex, Mylan Pharma, Sun Pharma, Orion Pharmaceuticals, ViroMed, Mitsubishi Tanabe Pharma America, AB Science, Orphazyme, among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the Global Amyotrophic Lateral Sclerosis (ALS) market. For instance, on October 22, 2020, Catalent and BrainStorm Cell Therapeutics Partnered to manufacture mesenchymal stem cell platform therapy NurOwn.

Sanofi

Overview:

Sanofi was founded in 1973 in Paris, France. Sanofi is a multinational pharmaceutical company engaged in the research, development and manufacturing of pharmaceutical drugs in the prescription market and over-the-counter drugs. Sanofi has Sanofi Pasteur, Genzyme, Shantha Biotechnics, Chattem, Ablynx, and Bioverativ as its subsidiaries.

Product Portfolio:

 Sanofi’s amyotrophic lateral sclerosis (ALS) product portfolio has RILUTEK (riluzole) Tablets.

The global amyotrophic lateral sclerosis (ALS) market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages. 

Frequently Asked Questions

What is the Projected CAGR value of the Amyotrophic Lateral Sclerosis (ALS) Market?

Amyotrophic Lateral Sclerosis (ALS) Market is expected to grow at a CAGR of 5.6% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Amyotrophic Lateral Sclerosis (ALS) Market during 2022-2029

Which is the fastest growing region in the Amyotrophic Lateral Sclerosis (ALS) Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period 

Trending Topics

Multiple Sclerosis Therapeutics Market

Systemic Sclerosis Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest